Thomas M Pisansky

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma
    Thomas M Pisansky
    Division of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 95:513-9. 2002
  2. ncbi request reprint Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression
    Matthew C Solhjem
    Division of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer J 10:343-8. 2004
  3. doi request reprint Late toxicity after postprostatectomy salvage radiation therapy
    JENNIFER L PETERSON
    Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Radiother Oncol 93:203-6. 2009
  4. doi request reprint Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter
    Christopher L Hallemeier
    Departments of Radiation Oncology Urology, Mayo Clinic, Rochester, MN Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ
    Am J Clin Oncol 36:596-600. 2013
  5. ncbi request reprint Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm
    Brian J Davis
    Division of Radiation Oncology, Mayo Clinic and Foundation, 200 First Street, SW Rochester, MN 55905, USA
    Brachytherapy 3:106-12. 2004
  6. ncbi request reprint Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy
    Matthew C Solhjem
    Division of Radiation Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 60:767-76. 2004
  7. ncbi request reprint External beam radiotherapy as curative treatment of prostate cancer
    Thomas M Pisansky
    Division of Radiation Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:883-98. 2005
  8. ncbi request reprint Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration
    Jeffrey S Eshleman
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 59:419-25. 2004
  9. doi request reprint Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 82:1938-43. 2012
  10. doi request reprint Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapy
    Nataliya Kovalchuk
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brachytherapy 11:111-8. 2012

Detail Information

Publications46

  1. ncbi request reprint The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma
    Thomas M Pisansky
    Division of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 95:513-9. 2002
    ..Predictive models based on pretherapy factors may be useful to estimate the likelihood for clinically relevant extraprostatic disease and may be incorporated into selection criteria for this procedure...
  2. ncbi request reprint Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression
    Matthew C Solhjem
    Division of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer J 10:343-8. 2004
    ..The purpose of this study is to examine the effect of NHT on prostate volume before permanent prostate brachytherapy (PPB) and on prostatic edema after PPB...
  3. doi request reprint Late toxicity after postprostatectomy salvage radiation therapy
    JENNIFER L PETERSON
    Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Radiother Oncol 93:203-6. 2009
    ..To evaluate late toxicity in patients who received salvage external beam radiotherapy (EBRT) for a detectable prostate-specific antigen (PSA) level after radical prostatectomy (RP)...
  4. doi request reprint Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter
    Christopher L Hallemeier
    Departments of Radiation Oncology Urology, Mayo Clinic, Rochester, MN Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ
    Am J Clin Oncol 36:596-600. 2013
    ..To report outcomes of multimodality therapy incorporating surgical resection and intraoperative electron radiotherapy (IOERT) for patients with locoregionally (LR) recurrent or advanced primary urothelial carcinoma...
  5. ncbi request reprint Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm
    Brian J Davis
    Division of Radiation Oncology, Mayo Clinic and Foundation, 200 First Street, SW Rochester, MN 55905, USA
    Brachytherapy 3:106-12. 2004
    ..Routine permanent prostate brachytherapy (PPB) includes CT-based postimplant dosimetry (PID). A method of identifying different source types from CT data in the same implant volume is described...
  6. ncbi request reprint Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy
    Matthew C Solhjem
    Division of Radiation Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 60:767-76. 2004
    ..To provide data relevant to evaluating the potential of TRUS-based image fusion for intraoperative dosimetry...
  7. ncbi request reprint External beam radiotherapy as curative treatment of prostate cancer
    Thomas M Pisansky
    Division of Radiation Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:883-98. 2005
    ....
  8. ncbi request reprint Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration
    Jeffrey S Eshleman
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 59:419-25. 2004
    ..To examine the incidence of seed migration detected on chest X-ray and to identify the predictors associated with its occurrence...
  9. doi request reprint Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 82:1938-43. 2012
    ....
  10. doi request reprint Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapy
    Nataliya Kovalchuk
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brachytherapy 11:111-8. 2012
    ..To quantify the dosimetric deviations that would arise from delivering subsequent prostate high-dose-rate fractions with only needle readjustment and no replanning after the first fraction...
  11. ncbi request reprint Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging
    John M Schallenkamp
    Division of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 63:800-11. 2005
    ..To describe the relative positions and motions of the prostate, pelvic bony anatomy, and intraprostatic gold fiducial markers during daily electronic portal localization of the prostate...
  12. ncbi request reprint Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy
    Richard Choo
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 98:773-6. 2006
  13. doi request reprint High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer
    Thomas M Pisansky
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1364-72. 2008
    ....
  14. doi request reprint Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis
    Johnny Ray Bernard
    Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Int J Radiat Oncol Biol Phys 76:735-40. 2010
    ....
  15. ncbi request reprint Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy
    David J Schwartz
    Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Brachytherapy 2:98-102. 2003
    ..To identify factors associated with radiation exposure (RE) to operating room personnel during transperineal interstitial permanent prostate brachytherapy (TIPPB)...
  16. ncbi request reprint Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device
    Michael G Herman
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 57:1131-40. 2003
    ..To develop a real-time electronic portal imaging device (EPID) procedure to identify intraprostatic gold markers and correct daily variations in target position during external beam radiotherapy for prostate cancer...
  17. doi request reprint Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma-The Mayo Clinic experience
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN
    Urol Oncol 32:24.e1-6. 2014
    ..The objectives of this study are to examine the long-term efficacy and adverse effects of adjuvant radiotherapy (RT) for stage I testicular seminoma...
  18. ncbi request reprint External-beam radiotherapy for localized prostate cancer
    Thomas M Pisansky
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 355:1583-91. 2006
  19. ncbi request reprint Patient-specific daily pretreatment setup protocol using electronic portal imaging for radiation therapy
    Michael H Wittmer
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
    J Appl Clin Med Phys 6:1-13. 2005
    ..This procedure resulted in a reduction in setup displacement that was statistically significant, clinically relevant, and approached that of a more typical patient group...
  20. ncbi request reprint Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer
    Thomas M Pisansky
    Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Urology 62:36-45. 2003
    ..The historical precedent for combining androgen suppression with radiotherapy is described, as are the results of prior definitive trials and ongoing studies in this setting...
  21. doi request reprint Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer
    Alexander S Parker
    College of Medicine, Mayo Clinic Florida, Jacksonville, FL 32224, USA
    Int J Radiat Oncol Biol Phys 75:1364-70. 2009
    ..Herein, we evaluate the ability of Ki-67 staining in primary prostate cancer to independently aid in the prediction of BCR among men undergoing SRT...
  22. pmc Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831
    Michele Y Halyard
    Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    J Clin Oncol 27:2638-44. 2009
    ..To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery or mastectomy...
  23. ncbi request reprint Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system
    Steven J Buskirk
    Department of Radiation Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Urol 176:985-90. 2006
    ..This study was performed to evaluate the results and prognostic factors associated with radiotherapy for a detectable serum prostate specific antigen level after radical prostatectomy...
  24. doi request reprint Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Urol Oncol 31:1832-8. 2013
    ..To report long-term outcomes of patients with stage II testicular seminoma treated with radiotherapy (RT)...
  25. ncbi request reprint Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer
    Brian J Davis
    Division of Radiation Oncology and Department of Urology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Curr Opin Urol 13:117-22. 2003
    ..The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject...
  26. pmc Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 29:4491-7. 2011
    ....
  27. ncbi request reprint Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
    James N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Breast Cancer Res Treat 98:217-22. 2006
    ....
  28. ncbi request reprint Electronic and film portal images: a comparison of landmark visibility and review accuracy
    Jon J Kruse
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 54:584-91. 2002
    ....
  29. ncbi request reprint Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 107:1496-502. 2006
    ....
  30. ncbi request reprint Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:915-28. 2003
    ..To report the long-term outcome for patients with Stage T1-T2 adenocarcinoma of the prostate definitively irradiated in the prostate-specific antigen (PSA) era...
  31. pmc Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    J Clin Oncol 25:2035-41. 2007
    ..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence...
  32. ncbi request reprint Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy
    Mary Feng
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 68:1417-23. 2007
    ..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
  33. ncbi request reprint Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
    N Engl J Med 349:17-26. 2003
    ..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse...
  34. ncbi request reprint Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0010, USA
    Urology 68:1257-62. 2006
    ..To determine whether nadir prostate-specific antigen (PSA) levels within 12 months (nadir PSA12) after completion of radiotherapy (RT) can be used as an early marker of recurrence risk...
  35. ncbi request reprint Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
    ..To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival...
  36. ncbi request reprint Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
    J Clin Oncol 20:4141-9. 2002
    ....
  37. ncbi request reprint Comparison of biochemical failure definitions for permanent prostate brachytherapy
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1487-93. 2006
    ..To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy...
  38. ncbi request reprint PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis
    Michael E Ray
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 64:1140-50. 2006
    ....
  39. ncbi request reprint INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:1167-74. 2002
    ..To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer...
  40. ncbi request reprint Long-term follow-up of radiotherapy for prostate cancer
    Thomas M Pisansky
    Int J Radiat Oncol Biol Phys 60:1663-4; author repply 1664. 2004
  41. ncbi request reprint Advanced prostate cancer and postoperative radiotherapy
    Thomas M Pisansky
    JAMA 297:950-1; author reply 951. 2007
  42. ncbi request reprint Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 173:797-802. 2005
    ..In this report we determined the sensitivity and specificity of several BF definitions using distant failure (DF) alone or clinical failure (CF), defined as local failure (LF) and/or DF...
  43. ncbi request reprint Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups
    Howard D Thames
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Department of Radiation Oncology, William Beaumont Hospital, Deroit, MI, USA
    Int J Radiat Oncol Biol Phys 65:975-81. 2006
    ....
  44. ncbi request reprint Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 62:956-64. 2005
    ..To prospectively assess health-related quality of life (HRQOL) during the first year after treatment with prostate brachytherapy (PB) alone for T1c-2a prostate cancer...
  45. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  46. ncbi request reprint Morbidity after brachytherapy for prostate adenocarcinoma
    Thomas M Pisansky
    Mayo Clin Proc 79:946-7; author reply 947-9. 2004